29 / 74 · 1:03 · Original AXON film
ARA-290 / cibinetide
The burned-in captions and transcript carry the scientific claims and their limitations. The visuals are conceptual illustrations, not validated molecular models or experimental images. The video has no voice or audio. The full explanation is visible on screen; optional accessible captions are available in the player.
Read every result in its study context. A cell experiment, animal model, exploratory analysis and controlled human trial answer different questions.
Prepared 05 November 2026. Regulatory status is jurisdiction- and date-specific. No claim of specialist review or exhaustive evidence coverage.
Transcript
EPO-derived research peptide
ARA-290, also called cibinetide, was designed from a region of erythropoietin. Researchers aimed to explore tissue-protection signaling separately from stimulation of red-blood-cell production. [1]
Human phase 2b study | 64 participants
Human studies have included people with sarcoidosis and small-fiber nerve problems. A 64-participant phase two-b trial measured corneal nerve-fiber abundance and other outcomes. [1]
Surrogate and patient outcomes differ
Changes in nerve-fiber measurements are scientifically interesting. They still need to be separated from reliable pain relief, everyday function, and durable benefit for a wider population. [1] [2]
Confirmatory evidence is still needed
A small, short study cannot settle long-term safety or show that all neuropathies respond. Cibinetide remains an experimental research story in these sources, not proof of a universal nerve-repair treatment. [1] [2]
Sources and context
These linked sources support the evidence distinctions in this short overview. This is not a systematic review, endorsement or treatment recommendation.
- Culver et al. (2017): Cibinetide and corneal nerve-fiber abundance in sarcoidosis →Design, 64 participants, nerve-fiber endpoints, and investigational rationale.
- EU Clinical Trials Register: ARA-290 phase 2 results, 2013-003016-45 →Dose-ranging exploratory study and disease-specific clinical context.
